In afternoon trade the S&P/ASX 200 index is on course to finish the day higher. At the time of writing the benchmark index is up 0.3% to 6,195.7 points.
Four shares that are climbing more than most on Friday are listed below. Here's why they are ending the week with a bang:
The Pilbara Minerals Ltd (ASX: PLS) share price is up a further 2% to 82 cents on Friday. The lithium miner's shares were up as much as 10% in early trade before fading this afternoon. Investors have been fighting to get hold of its shares following a series of positive announcements. These include the achievement of commercial production at its Pilgangoora project, the commencement of its partnering process to interconnect uncommitted Stage 3 offtake, and the potential sale of a minority interest of between 20% to 49% in the project.
The Super Retail Group Ltd (ASX: SUL) share price has pushed 5% higher to $8.00 despite there being no news out of the retail group. This latest gain means that Super Retail's shares have surged 17% higher since the start of the year. The catalyst for this was a strong half year result and positive guidance for the remainder of the financial year.
The Syrah Resources Ltd (ASX: SYR) share price has climbed 3.5% to $1.11 after the graphite miner provided an update on its mineral resource and ore reserves at the Balama project. Although it was a reasonably mixed update, one positive was that the mineral resource estimate for the Balama operation has been upgraded by 19% to 1,423Mt at an average grade of 10% total graphitic carbon
The Volpara Health Technologies Ltd (ASX: VHT) share price has rocketed 11% higher to $1.39. Today's gain appears to be related to a late announced on Thursday which revealed that the United States Food and Drug Administration has released a proposal to amend the Mammography Quality Standards Act to include a requirement that all US screening facilities provide information on breast density to women and their healthcare providers after a mammogram. This is expected to lead to an increased commercial opportunity for its Volpara Density clinical application.
